

Amendments to the Claims

This listing of the claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (currently amended) A wound healing composition comprising living human dermal fibroblast cells suspended within a single layered sterile, non-pyrogenic, solid or semi-solid, support matrix, said support matrix comprising a protein concentration of 3 to 12 mg.ml⁻¹ and a cell density of said human dermal fibroblasts of 450 to 2500 cells per mm², in which the cells have a wound healing phenotype, and in which the composition is single layered and said composition having has been incubated for up to about 8 days to allow development of the wound healing phenotype 16 to 24 h at about 37°C.

Claims 2-3 (cancelled)

4. (currently amended) The wound healing composition of claim 1, ~~in which the composition is stored~~ having been stored after incubation for up to about 40 days at a temperature of 2°C to 8°C ~~while retaining the wound healing phenotype.~~

Claims 5-7 (cancelled)

8. (previously presented) The wound healing composition of claim 1, in which the composition substantially excludes keratinocytes.
9. (previously presented) The wound healing composition of claim 1, in which the cells are actively synthetic or able to become actively synthetic rapidly.
10. (previously presented) The wound healing composition of claim 1, in which the cells are not proliferating or not senescent.

Claims 11-12 (cancelled)

13. (currently amended) The wound healing composition of claim 1, in which the matrix is a fibrin matrix comprises fibrin.

14. (currently amended) The wound healing composition of claim 13, in which the support matrix has a fibrin ~~has a~~ concentration in the range of 3 to 12 mg.ml⁻¹.
15. (currently amended) The wound healing composition of claim 13, in which the fibrin matrix ~~[[is]]~~ has been formed by thrombin-mediated polymerisation of fibrinogen.
16. (cancelled)
17. (previously presented) The wound healing composition of claim 1, further comprising a protease inhibitor.
18. (currently amended) The wound healing composition of claim 1, in which the composition ~~[[is]]~~ has been incubated in a protein-rich environment.
19. (previously presented) The wound healing composition of claim 1, in which the composition has a thickness of approximately 8 mm or less.

Claims 20-21 (cancelled)

23. (previously presented) The wound healing composition of claim 1, in which the composition is packaged in a container suitable for transporting the composition, storing the composition, or topically applying the composition to a skin surface.
24. (currently amended) The wound healing composition of claim 23, in which the container comprises a flexible pouch ~~consisting of~~ comprising two sheets of impermeable flexible material peripherally sealed to ~~provide a means of containment for~~ contain the composition, the pouch comprising a first internal surface to which the composition is adherent at a level of adhesion more than between the composition and a second internal surface of the pouch but less than that between the composition and the skin surface, such that in use the pouch may be opened by parting the sheets and the composition conveniently manipulated and directly applied to the skin surface without further requirement for the composition to be directly touched ~~directly by any other means~~ prior to application.

25. (currently amended) The wound healing composition of claim 23, in which the container is sterile ~~an Oliver™ Products Company "Solvent Resistant Peelable Pouching Material"~~ ~~(Product number Q15/48BF1)~~.
26. (previously presented) The wound healing composition of claim 1, for use as a medicament.
27. (previously presented) The wound healing composition of claim 1, for use as a medicament in the treatment of a skin lesion.
28. (previously presented) The wound healing composition of claim 26, wherein said medicament is used for topical application to a skin lesion.

Claims 29-38 (cancelled)

39. (currently amended) The wound healing composition of claim 4, in which the composition ~~[[is]]~~ has been stored after incubation for up to about 19 days.
40. (currently amended) The wound healing composition of claim 39, in which the composition ~~[[is]]~~ has been stored after incubation for about 7 to 14 days ~~or about 7 to 14 days~~.
41. (currently amended) The wound healing composition of claim 4, in which the composition ~~[[is]]~~ has been stored after incubation at a temperature of 3°C to 5°C.
42. (currently amended) The wound healing composition of claim 41, in which the composition ~~[[is]]~~ has been stored after incubation at a temperature of about 4°C.
43. (cancelled)
44. (currently amended) The wound healing composition of claim 6, in which said human dermal fibroblasts comprise between about 90% to 100% of the cells of said composition.
45. (cancelled)

46. (currently amended) The wound healing composition of claim ~~[[11]]~~ 1, in which the cells are suspended substantially uniformly within the matrix.
47. (cancelled)
48. (currently amended) The wound healing composition of claim 14, in which the support matrix has a fibrin ~~has a~~ concentration in the range of 3 to 5 mg.ml⁻¹ or 7 to 12 mg.ml⁻¹.
49. (previously presented) The wound healing composition of claim 17, wherein said protease inhibitor is aprotinin or tranexamic acid.
50. (previously presented) The wound healing composition of claim 19, in which the composition has a thickness of approximately 5 mm or less.
51. (previously presented) The wound healing composition of claim 28, wherein said skin lesion is a venous ulcer, diabetic ulcer, pressure sore, burn or iatrogenic grating wound.

Claims 52-62 (cancelled)